SpringWorks Therapeutics: Funding, Investors & Team (Oct 2026)
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two potentially registrational clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer.
SpringWorks Therapeutics has raised $225M across 1 funding round on record, the most recent a Post-IPO Equity of $225M announced in Sep 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SpringWorks Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2022.
SpringWorks Therapeutics Funding Rounds
SpringWorks Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
SpringWorks Therapeutics Funding Compared to Other Biotechnology Startups
SpringWorks Therapeutics' latest round of $225M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SpringWorks Therapeutics in Biotechnology and Stamford
Companies Similar to SpringWorks Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
SpringWorks Therapeutics Funding FAQs
What does SpringWorks Therapeutics do?
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two potentially registrational clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer.
How much funding has SpringWorks Therapeutics raised?
SpringWorks Therapeutics has raised $225M across 1 round on record. The most recent is a Post-IPO Equity of $225M announced in Sep 2022.
When did SpringWorks Therapeutics last raise funding?
SpringWorks Therapeutics' most recent funding round on record is a Post-IPO Equity of $225M, announced in Sep 2022.
Who is the CEO of SpringWorks Therapeutics?
Saqib Islam is listed as CEO at SpringWorks Therapeutics.
Where is SpringWorks Therapeutics headquartered?
SpringWorks Therapeutics is based in Stamford, Connecticut, United States.
How many employees does SpringWorks Therapeutics have?
SpringWorks Therapeutics is in the 101-250 employee band.
How does SpringWorks Therapeutics' funding compare to other Biotechnology startups?
SpringWorks Therapeutics' latest round of $225M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's SpringWorks Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SpringWorks Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.